← All candidates
One insider buy in the last year — $371.6K in all.
28 filings on record.
CNTBConnect Biopharma Holdings Ltd
NasdaqGM · Healthcare · $128.47M
$2.04
-32.17% · Sep 15
One insider buy in the last year — $371.6K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$128.47M
Float
21.1M
33% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
43.5
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Huang James
Bought $371.6K on May 29 — 150,000 sh @ $2.48, held indirect, 1.1% of their stake.
First Form 4 on file
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
27 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
Context
Wall St
$7.07 avg target
+246.6% vs today · 7 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 2 quarters beat
Q4 '25−$0.27 act+$0.03
Q3 '25−$0.31 act−$0.08
Coverage
Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026MarketBeat · 05-22Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite RiskySimply Wall St. · 05-15Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impressesMarketBeat · 03-30Connect Biopharma Touts “Next-Gen Dupixent” Rademikibart, Near-Term Asthma/COPD Readouts
The file stays open
28 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice